Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal microRNAs, miR-181a-5p and miR-324-5p act together to attenuate pulmonary vascular remodelling and that their actions are mediated by Notch4 and ETS1 and other key regulators of vascular homoeostasis. Expressions of KLF2, miR-181a-5p and miR-324-5p are reduced, while levels of their target genes are elevated in pre-clinical PAH, idiopathic PAH and heritable PAH with missense p.H288Y KLF2 mutation. Therapeutic supplementation of miR-181a-5p and miR-324-5p reduces proliferative and angiogenic responses in patient-derived cells and attenuates disease progression in PAH mice. This study shows that reduced KLF2 signalling is a common feature of human PAH and highlights the potential therapeutic role of KLF2-regulated exosomal miRNAs in PAH and other diseases associated with vascular remodelling.

Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension

Satta S.;Piva R.;
2020-01-01

Abstract

Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal microRNAs, miR-181a-5p and miR-324-5p act together to attenuate pulmonary vascular remodelling and that their actions are mediated by Notch4 and ETS1 and other key regulators of vascular homoeostasis. Expressions of KLF2, miR-181a-5p and miR-324-5p are reduced, while levels of their target genes are elevated in pre-clinical PAH, idiopathic PAH and heritable PAH with missense p.H288Y KLF2 mutation. Therapeutic supplementation of miR-181a-5p and miR-324-5p reduces proliferative and angiogenic responses in patient-derived cells and attenuates disease progression in PAH mice. This study shows that reduced KLF2 signalling is a common feature of human PAH and highlights the potential therapeutic role of KLF2-regulated exosomal miRNAs in PAH and other diseases associated with vascular remodelling.
2020
11
1
1185
1195
Adult; Aged; Animals; Cell Proliferation; Disease Models, Animal; Disease Progression; Endothelial Cells; Exosomes; Female; Gene Expression Regulation; Genetic Therapy; Humans; Kruppel-Like Transcription Factors; Lung; Male; Mice; MicroRNAs; Middle Aged; Mutation, Missense; Primary Cell Culture; Pulmonary Arterial Hypertension; Pulmonary Artery; Signal Transduction; Vascular Remodeling; Young Adult
Sindi H.A.; Russomanno G.; Satta S.; Abdul-Salam V.B.; Jo K.B.; Qazi-Chaudhry B.; Ainscough A.J.; Szulcek R.; Jan Bogaard H.; Morgan C.C.; Pullamsetti...espandi
File in questo prodotto:
File Dimensione Formato  
s41467-020-14966-x.pdf

Accesso aperto

Descrizione: Articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 3.08 MB
Formato Adobe PDF
3.08 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1766332
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 58
social impact